In the meta-analysis encompassing approximately 24,000 ovarian cancer patients from 53 studies and more than 100,000 controls, mutations in RAD51C were associated with a 5-fold elevated risk of ovarian cancer (OR = 5.59; 95%CI: 4.42–7.07; p < 0.0001) [16]. This evidence concerns the gene RAD51C and ovarian carcinoma.